anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
INTRODUCTION: Asthma exacerbations or 'attacks' can vary in severity from mild worsening of symptoms to life-threatening changes that require urgent hospital care. Understanding these exacerbations is crucial to improving treatment and support for patients. Electronic health records (EHR) using anonymised data from people with asthma in primary and secondary care can be used to understand exacerbations and outcomes. However, previous studies found significant heterogeneity in the algorithms used to define asthma exacerbations. Validating definitions of asthma exacerbations in EHR will lead to more robust and comparable evidence in future research.
METHODS AND ANALYSIS: Medline and Embase will be searched for the key concepts relating to asthma exacerbations, EHR and validation. All studies that validate exacerbations of asthma in EHR and administrative claims databases published before 30 May 2024 and written in English will be considered. Validated algorithms for asthma exacerbations or attacks must be compared against a reference or gold standard definition, and a measure of validity must be included. Articles will be screened for inclusion by two independent reviewers with any disagreements resolved by consensus or arbitration by a third reviewer. Study details will be extracted, and the risk of bias will be assessed using a QUADAS-2 tailored to this review.
ETHICS & DISSEMINATION: No ethical approval is required as this is a review of previously published literature. Results will be disseminated in a peer-reviewed journal with the aim of being used in future research to help identify asthma exacerbation in EHR.
PROSPERO REGISTRATION NUMBER: CRD42024545081.
The present invention describes the production of interferon- tau  proteins and polypeptides derived therefrom. The antiviral and anticellular proliferation properties of these proteins and polypeptides are disclosed. One advantage of the proteins of the present invention is that they do not have cytotoxic side-effects when used to treat cells. Structure/function relationships for the interferon- tau  protein are also described. In one aspect, the invention includes ovine interferon- tau . In another aspect the invention includes multiple forms of human interferon- tau .
The present invention relates to a paste preparation for treating psoriasis and a preparation technology thereof, which provides an externally applied medicine combining traditional Chinese medicines and Western medicines for treating psoriasis and a preparation technology thereof. The paste preparation is prepared by adopting the prescription of four Chinese medicinal plants including realgar, borneol, etc. and three chemicals including chlorpheniramine, etc., and vaseline is adopted as a base material. The preparation technology of the paste preparation for treating psoriasis comprises two technologies of raw medicinal materials pulverization and uniform grinding of vaseline to form paste. The paste preparation for treating psoriasis has the advantages of scientific and novel prescription, simple preparation technology, low production cost, convenience for spreading and no relapse. The paste preparation has the efficacy of killing psoriasis bacteria, eliminating dirt, evacuating pus, promoting tissue regeneration, relieving itch, nourishing the blood and moistening the skin. The paste preparation can effectively cure various kinds of psoriasis.
Excessive transforming growth factor β1 (TGF-β1) secreted by activated hepatic stellate cells (aHSCs) aggravates liver fibrosis via over-activation of TGF-β1-mediated signaling pathways in a TGF-β type I receptor (TβRI) dependent manner. TβRI with the C-terminal valine truncated (RIPΔ), as a novel TβRI-mimicking peptide, is an appealing anti-fibrotic candidate by competitive binding of TGF-β1 to block TGF-β1 signal transduction. Platelet-derived growth factor receptor β (PDGFβR) is highly expressed on the surface of aHSCs in liver fibrosis. Herein, we designed a novel RIPΔ variant Z-RIPΔ (PDGFβR-specific affibody ZPDGFβR fused to the N-terminus of RIPΔ) for liver fibrosis therapy, and expect to improve the anti-liver fibrosis efficacy by specifically inhibiting the TGF-β1 activity in aHSCs. Target peptide Z-RIPΔ was prepared in Escherichia coli by SUMO fusion system. Moreover, Z-RIPΔ specifically bound to TGF-β1-activated aHSCs, inhibited cell proliferation and migration, and reduced the expression of fibrosis markers (α-SMA and FN) and TGF-β1 pathway-related effectors (p-Smad2/3 and p-p38) in vitro. Furthermore, Z-RIPΔ specifically targeted the fibrotic liver, alleviated the liver histopathology, mitigated the fibrosis responses, and blocked TGF-β1-mediated Smad and p38 MAPK cascades. More importantly, Z-RIPΔ exhibited a higher fibrotic liver-targeting capacity and stronger anti-fibrotic effects than its parent RIPΔ. Besides, Z-RIPΔ showed no obvious toxicity effects in treating both an in vitro cell model and an in vivo mouse model of liver fibrosis. In conclusion, Z-RIPΔ represents a promising targeted candidate for liver fibrosis therapy.
ABSTRACT Provided are combinations, compositions and kits containing a hyaluronan degrading enzyme, such as a soluble hyaluronidase, for treatment of hyaluronan-associated conditions, diseases and disorders. In one example, the products include an additional agent or treatment. Such products can be used in methods for administering the products to treat the hyaluronan-associated diseases and conditions, for example, hyaluronan-associated cancers, for example, hyaluronan-rich tumors. The methods include administration of the hyaluronan degrading enzyme composition alone or in combination with other treatments.  Also provided are methods and compositions for providing sustained treatment effects in hyaluronan-.. associated diseases and conditions. Date Recue/Date Received 2020-10-16
PURPOSE: A pharmaceutical composite formulation containing a platelet aggregation inhibitor and an HMG-CoA reductase inhibitor is provided to improve stability of the platelet aggregation inhibitor and to reduce side effects on a gastrointestinal tract. CONSTITUTION: A pharmaceutical composite formulation comprises an inner layer, an intermediate layer, and an outer layer. The inner layer is prepared by coating an inner core with an enteric polymer. The inner core contains: a platelet aggregation inhibitor or a pharmaceutically acceptable salt thereof; an acidity regulator; and pharmaceutically acceptable additives. The intermediate layer contains water soluble polymers. The outer layer contains an HMG-CoA reductase inhibitor or a pharmaceutically acceptable salt thereof, and the pharmaceutically acceptable additives. The platelet aggregation inhibitor or the pharmaceutically acceptable salt is selected among aspirin, ticlopidine, clopidogrel, cilostazol, and sarpogrelate HCl.
The present invention relates to a feed additive and an injection of a yolk antibody resisting the diarrhea in sheep and a preparation method thereof. The feed additive and the injection of the yolk antibody resisting the diarrhea in sheep are extracted and prepared by the collected yolk of the immunized laying hens which are immunized by the univalent vaccines respectively prepared by sheep rotavirus, sheep colon bacillus and sheep clostridium welchil type-B or the combined vaccines prepared by the sheep rotavirus and/or the sheep colon bacillus and/or the sheep clostridium welchil type-B. The yolk antibody resisting the diarrhea in sheep prevents the diarrhea disease by improving the antibody level of a sheep organism for corresponding pathogenic microorganism causing the diarrhea. The present invention has beneficial effects that the feed additive of the yolk antibody resisting the diarrhea in sheep is convenient for feeding sheep and has obvious preventing and curing effect. The injection of the yolk antibody resisting the diarrhea in sheep is used after the sheep catches the disease, which has faster medicinal effect. The feed additive and a injection of a yolk antibody resisting the diarrhea in sheep and the preparation method thereof has obvious curative effect, low cost, fast acting, no toxic and side effect, no drug-resistant strain which can be produced, simple preparation, wide raw material source, convenient use and easy popularization.
Mitochondrial DNA mutations such as A3243G or A1555G are widely reported to cause hearing loss, but few reports exist on the A8296G mutation, which can also cause hearing loss. This report presents the case of a patient with the A8296G mutation and severe bilateral sensorineural hearing loss (SNHL) that progressed over two decades. The patient had no history of diabetes, but did have a family history of SNHL in her father and maternal grandmother. She was first diagnosed with SNHL at 45 years of age, and an A8296G mutation was found. The hearing threshold in the low-frequency range of the right ear was preserved at diagnosis, but eventually declined resulting in severe bilateral hearing loss by the age of 66 years, and cochlear implantation (CI) was performed in the left ear. The hearing threshold three months after CI was 25-45 dB HL, and the phoneme speech discrimination score in the left ear improved from 20% without CI to 74% with CI. SNHL patients with the A8295G mutation are good candidates for treatment with CI.
PURPOSE:To provide a gelling agent capable of forming an oily gel having high structural viscosity and excellent temperature stability, durability and water-repellency when added to a wide variety of oils, by treating a water- swelling clay mineral with a quaternary ammonium salt-type cationic surfactant and a composite lipid. CONSTITUTION:The objective gelling agent can be produced by treating (A) a water-swelling clay mineral [e.g. the colloidal hydrous aluminum silicate of formula I (X is Al, Fe, Mn or Cr; Y is Mg, Fe, Ni, Zn or Li; Z is K, Na or Ca), etc.] with (B) a quaternary ammonium salt-type cationic surfactant [e.g. the compound of formula II (R1 is 10-22C alkyl or benzyl; R2 is methyl or 10-22C alkyl; R3 and R4 are 1-3C alkyl or hydroxyalkyl; X is halogen or methyl sulfate residue), e.g. dodecyl trimethyl ammonium chloride] and (C) a composite lipid (e.g. lecithin).
The invention discloses oil-control acne-removing mite-removing face-cleaning facial cleanser containing deep sea salt and a preparation method thereof. The traditional Chinese medicine composition for removing mites contained in the facial cleanser can emit special fragrance with strong mite removing effect. The contained acne-removing traditional Chinese medicine composition has the effects of controlling grease secretion, dredging pores, inhibiting bacteria, disinfecting and removing acnes. The traditional Chinese medicine composition has synergistic effect, shows strong oil control, sterilization, mite removal and acne removal effects, has good effects of removing free radicals and inhibiting tyrosinase activity, and has certain anti-aging and whitening functions. The sea salt from dead sea has effects of promoting blood circulation, killing bacteria, relieving itching, relieving swelling and pain, whitening skin, removing cutin, acne, and blackhead. The components of the invention have synergistic effect, and show strong oil control, sterilization, mite removal and acne removal effects.
The focus of the first three sessions for participants receiving the tailored treatment will be their three most highly endorsed perceived risks of quitting. All participants will receive information about preparing for quit day in the second session and coping with withdrawal symptoms in the third session using the Mayo Clinic's "Smoke Free and Living It" manual. The last 5 counseling sessions will be based on perceived risks of quitting.
Over the past decade, novel methods for enrichment and identification of cancer cells circulating in the blood have been established. Blood-based detection of cancer cells and other tumor-associated products can be summarized under the term of Liquid Biopsy. Circulating tumor cells (CTCs) have been used for diagnosis, risk stratification and treatment selection as well as treatment monitoring in several studies over the past years, thus representing a valuable biomarker for cancer patients. A plethora of methods to enrich, detect and analyze CTCs has been established. In contrast to other liquid biopsy analytes (e.g. ctDNA), CTCs represent a viable analyte that provides a unique opportunity to understand the underlaying biology of cancer and the metastatic cascade on the molecular level. In this review, we provide an overview on the current methods used for enrichment, detection, molecular and functional characterization of CTCs.
The invention discloses an ejaculation unchoking preparation for treating ejaculatory incompetence and the preparation method thereof. The ejaculation unchoking preparation is prepared from the following medicament raw materials with proportions by weight: 300-600 parts of seed of garden balsam, 350-450 parts of fructus liquidambaris, 3-5 parts of chilopod, 360-510 parts of radix salviae miltiorrhizae, 180-260 parts of red paeonia, 30-60 parts of Chinese date, 200-450 parts of radix bupleuri and 80-130 parts of radix achyranthis bidentatae. The ejaculation unchoking preparation for treating the ejaculatory incompetence extracts the effective ingredients in the medicament raw materials by using a water cooking and extraction method and keeps the activity of the effective ingredients. Therefore, not only the dissolution rate of the effective ingredients in the medicament is improved greatly, but also the medicament is absorbed effectively, thereby improving the bioavailability. In addition, the medicine of the invention is a pure traditional Chinese medicine preparation, so that no toxic and side effects are existent after a patient uses for a long time, and the preparation has good safety. Moreover, the preparation method has the advantages of simple process and convenient operation.
Stable isotope labeling was used to measure dynamics of tubulin incorporation into microtubule subpopulations representing different neuronal compartments in the murine hippocampus. Neuronal microtubules were largely static. Basal turnover was highest in tau-associated (axona) and growth cone), lower in MAP2-associated (somatodendritic), and lowest in cold stable (axonal shaft) subpopulations. Intracerebroventricular glutamate injection stimulated label incorporation into axonal shaft and somatodendritic microtubules, the latter dependent on cAMP-PKA. Hippocampus-dependent memory formation after contextual fear conditioning was accompanied by increased assembly of MAP2- and cold stable-microtubules. Both microtubule assembly and memory formation were inhibited by the microtubule depolymerizing drug, nocodazole. This approach allows for correlation with behavioral measures of learning and memory and for the screening of candidate agents for stimulatory activities on learning memory.
OBJECTIVE: Spinal intramedullary ependymomas (IEs) represent a well-defined tumor entity usually warranting resection. Factors that determine full long-term neurological recovery after resection are seldomly reported on in larger clinical series. In this study, the authors aimed to highlight the neurological outcome of patients with IEs after resection, with a focus on full neurological recovery, and to explore possible risk factors for the absence of neurological amelioration to an optimal function after surgical treatment.
METHODS: A single-center retrospective analysis of all patients undergoing surgery for IEs between 2007 and 2021 was performed. Data collection included patient demographics, symptoms, clinical findings, histopathological diagnosis, surgical procedures, complications, and neurological outcome. Patients harboring a favorable outcome (modified McCormick Scale [mMS] grade of I) were compared with patients with a less favorable outcome (mMS grade ≥ II) at the final follow-up.
RESULTS: In total, 72 patients with a histologically diagnosed IE were included. IEs in those patients (41 males, 31 females; median age 51 [IQR 40-59] years) mostly occurred in the cervical (n = 40, 56%) or thoracic (n = 23, 32%) spine. Upon admission, motor deficits or gait deficits (mMS grade ≥ II) were present in 29 patients (40%), with a median mMS grade of II (IQR I-II). Gross-total resection was achieved in 60 patients (90%), and the rate of surgical complications was 7%. Histopathologically, 67 tumors (93%) were classified as WHO grade 2 ependymomas, 3 (4%) as WHO grade 1 subependymomas, and 2 (3%) as WHO grade 3 anaplastic ependymomas. After a mean follow-up of 863 ± 479 days, 37 patients (51%) had a fully preserved neurological function and 62 patients (86%) demonstrated an mMS grade of I or II. Comparison of favorable with unfavorable outcomes revealed an association of early surgery (within a year after symptom onset), the absence of ataxia or gait disorders, and a low mMS grade with full neurological recovery at the final follow-up. A subgroup of patients (n = 15, 21%) had nonresolving deterioration at the final follow-up, with no significant differences in relevant variables compared with the rest of the cohort.
CONCLUSIONS: The data presented solidify the role of early surgery in the management of spinal IEs, especially in patients with mild neurological deficits. Furthermore, the presence of gait disturbance or ataxia confers a higher risk of incomplete long-term recovery after spinal ependymoma resection. Because a distinct subgroup of patients had nonresolving deterioration, even when presenting with an uneventful history, further analyses into this subgroup of patients are required.
Coronary heart disease is still the commonest cause of death in the UK (in the main as a consequence of acute myocardial infarction (AMI)). Presently, timely and effective reperfusion with primary percutaneous coronary intervention (PPCI) remains the most effective treatment strategy for limiting infarct size, preserving left ventricular ejection fraction (LVEF), and improving the clinical outcomes in such patients. However, substantial mortality and morbidity rates still persist with respect to longer term outcome. One of the main determinants of prognosis after AMI is the size of the infarct. Thus, identification of additional strategies that might decrease infarct size is desirable.

Evidence from pre-clinical studies suggests that inorganic nitrite administration reduces infarct size in animal models of AMI. In this study we aim to translate these findings into man. We will test the hypothesis that in patients with STEMI undergoing PPCI, an intra-coronary injection of nitrite, initiated prior to establishment of full reperfusion reduces infarct size through prevention of ischemia-reperfusion injury.
PURPOSE: Provided are a smoking material for medical treatment and a manufacturing method thereof to release various symptoms of diseases with easily applying anytime and anywhere, and to improve immunity by manufacturing the smoking material with herbal medicines, sugar syrup and glycerin. CONSTITUTION: The smoking material is manufactured by mixing ginkgo leaf 20-30wt.%, at least 10 kinds of herbal medicines 70-80wt.%, sugar syrup 1-10wt.% and glycerin 0.1-1wt.%. The herbal medicines are selected from Santsigu Tuber, Puerariae Radix, Lycii Cortex Radicie, Pinelliae Rhizoma, Angelicae gigantis Radix, Cnidii Rhizoma, Paeoniae Radix, Zedoariae Rhizoma, Astragali Radix, Gastrodiae Rhizoma, Cassia cortex, Caryophylli flos, Olihanum, Myrrha, Chrysanthemi flos, Torilis fructus, Foeniculi fructus, Hoelen, Platycodi radix, Aurantii nohilis pericarpium, Evodiae fructus, Cartaegi fructus and Glycyrrhizae radix. The ginkgo leaves and herbal medicines are hydrothermally extracted to have a moisture content of 18-21% and aged in a sealed container for 10-20 days. The aged ingredients are dehydrofrozen to have a moisture content of 13-14%. Sugar syrup and glycerin are added in the ingredients and the moisture content is controlled to 12-13% for manufacturing as a cigarette.
Distraction is a growing and large public health problem with estimated societal harm due to distracted driving alone at $123 billion. In the age of texting, social media and computer pop-ups, distractions are unavoidable. There are no known interventions specifically developed to reduce distractions from interfering with attention. This project will test a treatment that combines virtual reality (VR) technology with habituation learning and exposure therapy to reduce the ability of distractors to interfere with learning and attention in children who are highly susceptible to being distracted. The investigators will test the treatment in children with symptoms of attention-deficit/hyperactivity disorder (ADHD) as they represent an enriched sample experiencing impairing distractibility that interferes with their daily functioning. The investigators hypothesize that children who suffer from severe distractibility can learn to ignore the distractors and improve their attention in VR therapy that simulates environments requiring focused attention. The neural targets of the therapy are both proactive and reactive control mechanisms used to suppress distractor processing. The investigators will assess how well VR therapy is at modulating distractor suppression via saccade metrics and measure the frequency of oculomotor capture by distractors as well as the efficiency of distractor suppression before and after therapy. Changes in head movement toward distractors, parent and teacher ADHD rating scales and improved performance on attention-demanding tasks will further assess success of the therapy and its ability to generalize to novel environments. Children will practice computer exercises at home using a VR headset that simulates a classroom environment with a high rate of distractors. Children will be performing attention-demanding tasks as if they were in a classroom with the intensity and rate of presentation of the personalized distractions (e.g., peers talking, teacher walking by) adapted according to the child's performance. With today's low-cost VR-gaming technology, children will be able to participate in habituation treatment sessions at-home, several times a week, using a lightweight and comfortable VR gaming headset.

In this "fast fail" test of the VR therapy, the project will assess the preliminary success and feasibility of VR training to modify saccades to distractors in an adaptive training versus nonadaptive training scenario. Data from this trial will determine whether to go forward for a subsequent confirmatory study.
The bone marrow adjusts blood cell production to meet physiological demands in response to insults. The spatial organization of normal and stress responses are unknown owing to the lack of methods to visualize most steps of blood production. Here we develop strategies to image multipotent haematopoiesis, erythropoiesis and lymphopoiesis in mice. We combine these with imaging of myelopoiesis1 to define the anatomy of normal and stress haematopoiesis. In the steady state, across the skeleton, single stem cells and multipotent progenitors distribute through the marrow enriched near megakaryocytes. Lineage-committed progenitors are recruited to blood vessels, where they contribute to lineage-specific microanatomical structures composed of progenitors and immature cells, which function as the production sites for each major blood lineage. This overall anatomy is resilient to insults, as it was maintained after haemorrhage, systemic bacterial infection and granulocyte colony-stimulating factor (G-CSF) treatment, and during ageing. Production sites enable haematopoietic plasticity as they differentially and selectively modulate their numbers and output in response to insults. We found that stress responses are variable across the skeleton: the tibia and the sternum respond in opposite ways to G-CSF, and the skull does not increase erythropoiesis after haemorrhage. Our studies enable in situ analyses of haematopoiesis, define the anatomy of normal and stress responses, identify discrete microanatomical production sites that confer plasticity to haematopoiesis, and uncover unprecedented heterogeneity of stress responses across the skeleton.